NYSE:MNK - Mallinckrodt News Headlines

Sign in or create an account to add this stock to your watchlist.
$18.92 +0.39 (+2.10 %)
(As of 12/18/2018 09:44 AM ET)
Previous Close$18.53
Today's Range$18.6101 - $19.02
52-Week Range$11.65 - $36.65
Volume91,128 shs
Average Volume2.50 million shs
Market Capitalization$1.60 billion
P/E Ratio2.53
Dividend YieldN/A
Beta1.62

Headlines

Mallinckrodt (NYSE MNK) News Headlines

Source:
DateHeadline
Mallinckrodt (MNK) Rating Reiterated by MizuhoMallinckrodt (MNK) Rating Reiterated by Mizuho
www.americanbankingnews.com - December 17 at 9:42 AM
A New Spin On MallinckrodtA New Spin On Mallinckrodt
seekingalpha.com - December 17 at 8:37 AM
Mallinckrodt To Present At 37th Annual J.P. Morgan Healthcare ConferenceMallinckrodt To Present At 37th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - December 17 at 8:36 AM
Is Mallinckrodt Public Limited Company (MNK) A Good Stock To Buy?Is Mallinckrodt Public Limited Company (MNK) A Good Stock To Buy?
finance.yahoo.com - December 16 at 8:30 AM
Does Mallinckrodt Have A Charitable Issue?Does Mallinckrodt Have A Charitable Issue?
seekingalpha.com - December 14 at 5:29 PM
Mallinckrodts Roxicodone Reformulation Gets CRL From FDAMallinckrodt's Roxicodone Reformulation Gets CRL From FDA
www.zacks.com - December 13 at 10:05 AM
Mallinckrodt Plc (MNK) CEO Mark Trudeau Presents at BMO Prescriptions for Success Healthcare Brokers Conference (Transcript)Mallinckrodt Plc (MNK) CEO Mark Trudeau Presents at BMO Prescriptions for Success Healthcare Brokers Conference (Transcript)
seekingalpha.com - December 12 at 4:05 PM
FDA Snubs Mallinckrodts Abuse-Deterrent Opioid ReformulationFDA Snubs Mallinckrodt's Abuse-Deterrent Opioid Reformulation
feeds.benzinga.com - December 12 at 10:58 AM
FDA rejects Mallinckrodts marketing application for abuse-deterrent oxycodone; shares down 2% premarketFDA rejects Mallinckrodt's marketing application for abuse-deterrent oxycodone; shares down 2% premarket
seekingalpha.com - December 12 at 8:39 AM
Mallinckrodt shares slide 4% premarket after pain treatment approval delayedMallinckrodt shares slide 4% premarket after pain treatment approval delayed
www.marketwatch.com - December 12 at 8:39 AM
FDA declines to approve reformulated Mallinckrodt opioidFDA declines to approve reformulated Mallinckrodt opioid
www.nasdaq.com - December 12 at 8:39 AM
Mallinckrodt PLC (MNK) Receives Consensus Rating of "Hold" from AnalystsMallinckrodt PLC (MNK) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - December 12 at 1:40 AM
Mallinckrodt PLC (MNK) Insider Mark Trudeau Purchases 1,000 SharesMallinckrodt PLC (MNK) Insider Mark Trudeau Purchases 1,000 Shares
www.americanbankingnews.com - December 11 at 10:19 AM
Mallinckrodt (MNK) Given a $27.00 Price Target by Wells Fargo & Co AnalystsMallinckrodt (MNK) Given a $27.00 Price Target by Wells Fargo & Co Analysts
www.americanbankingnews.com - December 7 at 1:21 PM
Piper Jaffray Companies Reiterates "$39.00" Price Target for Mallinckrodt (MNK)Piper Jaffray Companies Reiterates "$39.00" Price Target for Mallinckrodt (MNK)
www.americanbankingnews.com - December 7 at 12:17 PM
Mallinckrodt plc -- Moodys: Mallinckrodts proposed specialty generics spin-off is credit negativeMallinckrodt plc -- Moody's: Mallinckrodt's proposed specialty generics spin-off is credit negative
finance.yahoo.com - December 7 at 8:33 AM
Mallinckrodt PLC (MNK) Expected to Post Quarterly Sales of $642.50 MillionMallinckrodt PLC (MNK) Expected to Post Quarterly Sales of $642.50 Million
www.americanbankingnews.com - December 7 at 2:52 AM
Notable Two Hundred Day Moving Average Cross - MNKNotable Two Hundred Day Moving Average Cross - MNK
www.nasdaq.com - December 6 at 5:18 PM
Mallinckrodt Lower After Announcing Spin-Off Of Specialty Generics BusinessMallinckrodt Lower After Announcing Spin-Off Of Specialty Generics Business
www.nasdaq.com - December 6 at 5:18 PM
Mallinckrodt to spin off generics business, but to keep options openMallinckrodt to spin off generics business, but to keep options open
www.reuters.com - December 6 at 5:18 PM
Shares of Mallinckrodt Pharmaceuticals up 0.5% after company announces generics business spin-offShares of Mallinckrodt Pharmaceuticals up 0.5% after company announces generics business spin-off
www.marketwatch.com - December 6 at 5:18 PM
Why Is Mallinckrodt (MNK) Down 24.8% Since Last Earnings Report?Why Is Mallinckrodt (MNK) Down 24.8% Since Last Earnings Report?
www.zacks.com - December 6 at 5:18 PM
Mallinckrodt to spin off generic drugs business; specialty drugs to be based in New JerseyMallinckrodt to spin off generic drugs business; specialty drugs to be based in New Jersey
finance.yahoo.com - December 6 at 5:18 PM
BRIEF-Mallinckrodt Plans Spin-Off Of Specialty Generics Business To ShareholdersBRIEF-Mallinckrodt Plans Spin-Off Of Specialty Generics Business To Shareholders
www.msn.com - December 6 at 8:39 AM
Mallinckrodt Plans Spin-Off of Specialty Generics Business to ShareholdersMallinckrodt Plans Spin-Off of Specialty Generics Business to Shareholders
finance.yahoo.com - December 6 at 8:39 AM
Mallinckrodt plans to spin off specialty generics businessMallinckrodt plans to spin off specialty generics business
finance.yahoo.com - December 6 at 8:39 AM
Zacks: Brokerages Expect Mallinckrodt PLC (MNK) Will Post Earnings of $1.91 Per ShareZacks: Brokerages Expect Mallinckrodt PLC (MNK) Will Post Earnings of $1.91 Per Share
www.americanbankingnews.com - December 5 at 3:15 PM
Is Mallinckrodt Public Limited Company (NYSE:MNK) A Volatile Stock?Is Mallinckrodt Public Limited Company (NYSE:MNK) A Volatile Stock?
finance.yahoo.com - December 4 at 5:25 PM
Why Mallinckrodt Stock Sank TodayWhy Mallinckrodt Stock Sank Today
finance.yahoo.com - December 4 at 8:42 AM
Mallinckrodt defends Acthar Gel; shares up a fraction premarketMallinckrodt defends Acthar Gel; shares up a fraction premarket
seekingalpha.com - November 27 at 5:04 PM
Mallinckrodt Sees Unusually Large Options Volume (MNK)Mallinckrodt Sees Unusually Large Options Volume (MNK)
www.americanbankingnews.com - November 27 at 8:18 AM
Bearish Citron tweets pressure Mallinckrodt, down 11%Bearish Citron tweets pressure Mallinckrodt, down 11%
seekingalpha.com - November 26 at 5:07 PM
Mallinckrodt plc (MNK) Investigated by Block & Leviton LLP For Violations of Federal Securities LawsMallinckrodt plc (MNK) Investigated by Block & Leviton LLP For Violations of Federal Securities Laws
finance.yahoo.com - November 26 at 5:07 PM
5 Top Stock Trades for Tuesday: GE, GM and Cyber Monday5 Top Stock Trades for Tuesday: GE, GM and Cyber Monday
investorplace.com - November 26 at 4:15 PM
Canaccord Genuity Analysts Give Mallinckrodt (MNK) a $40.00 Price TargetCanaccord Genuity Analysts Give Mallinckrodt (MNK) a $40.00 Price Target
www.americanbankingnews.com - November 26 at 8:01 AM
Why One Top Drug Stock Could Have Nearly 30% UpsideWhy One Top Drug Stock Could Have Nearly 30% Upside
247wallst.com - November 20 at 5:08 PM
Opioid Industry Fights Efforts to Make It Pay for CrisisOpioid Industry Fights Efforts to Make It Pay for Crisis
www.wsj.com - November 19 at 5:09 PM
Mallinckrodt up 3% as Canaccord joins bull campMallinckrodt up 3% as Canaccord joins bull camp
seekingalpha.com - November 19 at 5:09 PM
Canaccord Genuity Upgrades Mallinckrodt plc (MNK) to BuyCanaccord Genuity Upgrades Mallinckrodt plc (MNK) to Buy
www.streetinsider.com - November 19 at 5:09 PM
Mallinckrodt Stock Can Rally Another 27%, Says AnalystMallinckrodt Stock Can Rally Another 27%, Says Analyst
finance.yahoo.com - November 19 at 5:09 PM
Canaccord Turns Bullish On Mallinckrodt: 4 Reasons WhyCanaccord Turns Bullish On Mallinckrodt: 4 Reasons Why
finance.yahoo.com - November 19 at 5:09 PM
Mallinckrodt Gets FDA Committee Vote for Abuse-Deterrent DrugMallinckrodt Gets FDA Committee Vote for Abuse-Deterrent Drug
finance.yahoo.com - November 15 at 5:11 PM
Mallinckrodt Plc (MNK) Presents at Jefferies London Healthcare Broker Conference Call (Transcript)Mallinckrodt Plc (MNK) Presents at Jefferies London Healthcare Broker Conference Call (Transcript)
seekingalpha.com - November 15 at 8:35 AM
Mallinckrodts SpecGx LLC Reports on Outcome of FDA Joint Advisory Committee on Abuse-Deterrent, Immediate-Release Reformulation of Roxicodone® (Oxycodone Hydrochloride)Mallinckrodt's SpecGx LLC Reports on Outcome of FDA Joint Advisory Committee on Abuse-Deterrent, Immediate-Release Reformulation of Roxicodone® (Oxycodone Hydrochloride)
finance.yahoo.com - November 15 at 8:35 AM
FDA advisory committee backs Mallinckrodts abuse-deterrent oxycodoneFDA advisory committee backs Mallinckrodt's abuse-deterrent oxycodone
seekingalpha.com - November 14 at 5:07 PM
Ad Com approaches for Mallinckrodts abuse-deterrent oxycodoneAd Com approaches for Mallinckrodt's abuse-deterrent oxycodone
seekingalpha.com - November 14 at 8:27 AM
Mallinckrodt plc (MNK) PT Raised to $29 at Mizuho SecuritiesMallinckrodt plc (MNK) PT Raised to $29 at Mizuho Securities
www.streetinsider.com - November 13 at 5:02 PM
Mallinckrodt To Present At BMO Prescriptions For Success Healthcare ConferenceMallinckrodt To Present At BMO Prescriptions For Success Healthcare Conference
www.marketwatch.com - November 13 at 8:27 AM
Mallinckrodt Presents Terlipressin Clinical Data at The Liver Meeting® 2018Mallinckrodt Presents Terlipressin Clinical Data at The Liver Meeting® 2018
finance.yahoo.com - November 9 at 8:42 AM
Mallinckrodt (MNK) Tops Q3 EPS by 30c, Revenues Beat; Offers FY18 EPS Guidance Above ConsensusMallinckrodt (MNK) Tops Q3 EPS by 30c, Revenues Beat; Offers FY18 EPS Guidance Above Consensus
www.streetinsider.com - November 7 at 8:38 AM
This page was last updated on 12/18/2018 by MarketBeat.com Staff

Featured Article: Swap

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel